Article
|
Open Access
Featured
-
-
Article |
Structural basis for ligand reception by anaplastic lymphoma kinase
Analysis of crystal structures of anaplastic lymphoma kinase elucidate the mechanism by which ligand binding and the glycine-rich domain regulate its activity.
- Tongqing Li
- , Steven E. Stayrook
- & Daryl E. Klein
-
Article |
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
An engineered IgM antibody administered intranasally in mice shows high prophylactic efficacy and therapeutic efficacy against SARS-CoV-2, and is also effective against multiple variants of concern that are resistant to IgG-based therapeutics.
- Zhiqiang Ku
- , Xuping Xie
- & Zhiqiang An
-
Article |
Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice
The bispecific IgG1-like CoV-X2 prevents SARS-CoV-2 spike binding to ACE2, neutralizes SARS-CoV-2 and its variants of concern, protects against disease in a mouse model, whereas the parental monoclonal antibodies generate viral escape.
- Raoul De Gasparo
- , Mattia Pedotti
- & Luca Varani
-
Article |
Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection
An antibody Fc domain variant with enhanced binding to an activating Fc receptor on dendritic cells promotes the induction of a protective CD8 T cell response.
- Stylianos Bournazos
- , Davide Corti
- & Jeffrey V. Ravetch
-
Article |
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
The monoclonal antibody S309, identified from memory B cells of an individual infected with SARS-CoV in 2003, or antibody cocktails that contain this antibody potently neutralize SARS-CoV-2.
- Dora Pinto
- , Young-Jun Park
- & Davide Corti
-
Letter |
G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody
Determination of the crystal structure of the human A2A adenosine receptor in complex with an inverse-agonist antibody shows that the allosteric site of the receptor inhibits agonist binding and that the antibody locks the receptor in an inactive conformation.
- Tomoya Hino
- , Takatoshi Arakawa
- & Takeshi Murata
-
Letter |
Antibody-based protection against HIV infection by vectored immunoprophylaxis
A single injection of a viral vector that encodes antibodies able to neutralize most HIV strains protects humanized mice from HIV infection.
- Alejandro B. Balazs
- , Joyce Chen
- & David Baltimore
-
News |
Antibody offers hope for multiple sclerosis treatment
Promising phase III trial paves the way for alemtuzumab approval.
- Duncan Graham-Rowe
-
Research Highlights |
Antibody search hits gold
-
News |
Engineered antibodies cross blood–brain barrier
Technique could be used to design therapies for Alzheimer's and other diseases.
- Heidi Ledford
-
Letter |
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits
Systemic amyloidosis is a serious disease caused by accumulation of amyloid fibrils in the viscera and connective tissues. Serum amyloid P component (SAP) is a normal plasma protein that concentrates within the amyloid deposits. These authors find that a combination of a drug that depletes circulating SAP and an antibody that targets residual SAP within the deposits results in clearance of amyloid deposits in a mouse model of the disease.
- Karl Bodin
- , Stephan Ellmerich
- & Mark B. Pepys
-
News |
Souped-up antibody fends off HIV
Targeted search yields proteins that neutralize nearly all HIV strains.
- Heidi Ledford
Computationally restoring the potency of a clinical antibody against Omicron